Song Chengyang, Yang Xueying
The Department of Thoracic and Cardiovascular Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Front Oncol. 2022 Apr 14;12:834585. doi: 10.3389/fonc.2022.834585. eCollection 2022.
Osimertinib is a third-generation, irreversible mutant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Osimertinib is currently the first line drug recommended by National Comprehensive Cancer Network (NCCN) guidelines against lung cancer harboring the EGFR TKI-sensitive mutation and acquired EGFR T790M resistance mutation. Osimertinib demonstrated some efficacy in clinical trials and case reports in patients bearing certain uncommon EGFR mutations, but it is not active in patients with other mutations such as C797S. This mini-review presents the mechanisms underlying the variations in patient responses, discusses the use of osimertinib against non-small-cell lung carcinomas with uncommon EGFR mutations, and addresses the future prospects of osimertinib-centered therapy.
奥希替尼是一种第三代不可逆的突变型表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，已获美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准。奥希替尼目前是美国国立综合癌症网络（NCCN）指南推荐用于治疗携带EGFR TKI敏感突变并获得EGFR T790M耐药突变的肺癌的一线药物。奥希替尼在针对某些罕见EGFR突变患者的临床试验和病例报告中显示出一定疗效，但对其他突变如C797S的患者无活性。本综述介绍了患者反应差异背后的机制，讨论了奥希替尼在治疗具有罕见EGFR突变的非小细胞肺癌中的应用，并探讨了以奥希替尼为中心的治疗的未来前景。
